A J van der Lelij

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. doi request reprint Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY
    A J van der Lely
    Department of Medicine, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 97:1589-97. 2012
  2. ncbi request reprint [One episode of cancer, always a patient]
    Aart Jan van der Lelij
    Erasmus Medisch Centrum, afd Interne Geneeskunde, Rotterdam, The Netherlands
    Ned Tijdschr Geneeskd 156:A4475. 2012
  3. pmc Justified and unjustified use of growth hormone
    A J van der Lely
    Department of Internal Medicine, Erasmus MC, 40 Dr Molewaterplein, 3015 GD Rotterdam, The Netherlands
    Postgrad Med J 80:577-80. 2004
  4. ncbi request reprint Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin
    Aart J van der Lely
    Department of Internal Medicine, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands
    Endocr Rev 25:426-57. 2004
  5. ncbi request reprint Growth hormone and glucose metabolism: the model of the GH-receptor antagonists
    A J van der Lely
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Erasmus Medical Center, 40 Dr Molewaterplein, 3015 GD Rotterdam, The Netherlands
    Ann Endocrinol (Paris) 65:81-3. 2004
  6. ncbi request reprint The medical treatment of acromegaly
    Aart Jan van der Lely
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Endokrynol Pol 58:361-3. 2007
  7. doi request reprint Ghrelin and new metabolic frontiers
    Aart Jan van der Lely
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Horm Res 71:129-33. 2009
  8. doi request reprint Multiple sources of information for the hypothalamus
    A J van der Lelij
    Erasmus University Medical Center, Department of Medicine, Rotterdam, The Netherlands
    Front Horm Res 38:190-5. 2010
  9. doi request reprint Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone
    Aart Jan van der Lely
    Department of Internal Medicine, Erasmus University MC, 40 Dr Molewaterplein, 3015 GD Rotterdam, The Netherlands
    Eur J Endocrinol 164:325-33. 2011
  10. ncbi request reprint Growth hormone receptor antagonists
    A J van der Lely
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Neuroendocrinology 83:264-8. 2006

Collaborators

Detail Information

Publications22

  1. doi request reprint Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY
    A J van der Lely
    Department of Medicine, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 97:1589-97. 2012
    ..Pegvisomant is a GH receptor antagonist. The ACROSTUDY is a global safety surveillance study of long-term treatment of acromegaly with pegvisomant...
  2. ncbi request reprint [One episode of cancer, always a patient]
    Aart Jan van der Lelij
    Erasmus Medisch Centrum, afd Interne Geneeskunde, Rotterdam, The Netherlands
    Ned Tijdschr Geneeskd 156:A4475. 2012
    ..Not only physicians, but also insurance companies and medical authorities should address the change in the medical requirements of this new type of patient with very specific medical problems...
  3. pmc Justified and unjustified use of growth hormone
    A J van der Lely
    Department of Internal Medicine, Erasmus MC, 40 Dr Molewaterplein, 3015 GD Rotterdam, The Netherlands
    Postgrad Med J 80:577-80. 2004
    ..Moreover, there are no available study data to indicate that the use of GH for non-GH deficient subjects should be advocated, especially as animal data suggest that lower GH levels are positively correlated with longevity...
  4. ncbi request reprint Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin
    Aart J van der Lely
    Department of Internal Medicine, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands
    Endocr Rev 25:426-57. 2004
    ..So, there is indeed a possibility that ghrelin analogs, acting as either agonists or antagonists, might have clinical impact...
  5. ncbi request reprint Growth hormone and glucose metabolism: the model of the GH-receptor antagonists
    A J van der Lely
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Erasmus Medical Center, 40 Dr Molewaterplein, 3015 GD Rotterdam, The Netherlands
    Ann Endocrinol (Paris) 65:81-3. 2004
    ..However, there are simply no data available that might support a role for pegvisomant treatment in disorders in which glucose metabolism is disturbed and in which reducing GH action would be theoretically beneficial...
  6. ncbi request reprint The medical treatment of acromegaly
    Aart Jan van der Lely
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Endokrynol Pol 58:361-3. 2007
    ..To date we have not moved as far as this, but awareness of treatment-specific differential effects might help us to understand some of the signs and symptoms that we encounter in acromegalic patients...
  7. doi request reprint Ghrelin and new metabolic frontiers
    Aart Jan van der Lely
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Horm Res 71:129-33. 2009
    ..Conclusions: AG and UAG play an important regulatory role in metabolism...
  8. doi request reprint Multiple sources of information for the hypothalamus
    A J van der Lelij
    Erasmus University Medical Center, Department of Medicine, Rotterdam, The Netherlands
    Front Horm Res 38:190-5. 2010
    ..This review will address some of the developments that illustrate how sophisticated these ancient mechanism of cross-talk are and what they could mean to us as highly developed 'modern' mammals...
  9. doi request reprint Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone
    Aart Jan van der Lely
    Department of Internal Medicine, Erasmus University MC, 40 Dr Molewaterplein, 3015 GD Rotterdam, The Netherlands
    Eur J Endocrinol 164:325-33. 2011
    ..To evaluate the efficacy and safety of coadministered lanreotide Autogel (LA; 120  mg/month) and pegvisomant (40-120  mg/week) in acromegaly...
  10. ncbi request reprint Growth hormone receptor antagonists
    A J van der Lely
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Neuroendocrinology 83:264-8. 2006
    ..Also, pegvisomant monotherapy is administered once daily and is very costly. Combined treatment of a somatostatin analog with pegvisomant appears to be an effective and rational approach...
  11. ncbi request reprint Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly
    Sebastian J C M M Neggers
    Department of Internal Medicine, Erasmus University MC Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 92:4598-601. 2007
    ..We previously reported the efficacy of a combined treatment of active acromegaly with both long-acting somatostatin analogs (SSA) and pegvisomant (PEG-V)...
  12. ncbi request reprint Diagnostic imaging of dopamine receptors in pituitary adenomas
    Wouter W de Herder
    Departments of Internal Medicine and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Eur J Endocrinol 156:S53-6. 2007
    ..Dopamine D2 receptors on pituitary tumours can also be studied using positron emission tomography with (11)C-N-raclopride and (11)C-N-methylspiperone...
  13. ncbi request reprint Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
    Wouter W de Herder
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Eur J Endocrinol 155:717-23. 2006
    ..We have studied the correlation between in vivo imaging of D2 receptors using (123)I-epidepride and the radiological response of NFPA to DA in 18 patients...
  14. ncbi request reprint Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune system
    Virgil A Dalm
    Department of Internal Medicine, Erasmus Medical Center, 3015 GD, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 88:270-6. 2003
    ..On the basis of these observations, we hypothesize a role for CST as an endogenous ligand of at least the sst2 receptor in the human immune system, rather than SS itself...
  15. ncbi request reprint Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly
    Wouter W de Herder
    Section of Endocrinology, Department of Internal Medicine, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur J Endocrinol 153:67-71. 2005
    ..To study whether the growth hormone (GH) response after the subcutaneous administration 50 microg of octreotide (acute octreotide test) has any predictive value for long-term IGF-I normalization with Sandostatin LAR...
  16. ncbi request reprint Distribution pattern of somatostatin and cortistatin mRNA in human central and peripheral tissues
    Virgil A S H Dalm
    Department of Internal Medicine, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 60:625-9. 2004
    ..Further studies demonstrated a selective expression of CST in tissues and cells of the human immune system, while SS was not expressed...
  17. ncbi request reprint The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro
    Leo J Hofland
    Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:1577-85. 2004
    ..Second, compared with OCT, SOM230 is more potent in inhibiting PRL release by mixed GH/PRL-secreting adenoma and prolactinoma cells...
  18. ncbi request reprint A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients
    Joost van der Hoek
    Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:638-45. 2004
    ..We conclude that SOM230 is an effective GH-lowering drug in acromegalic patients with the potential to increase the number of patients controlled during long-term medical treatment...
  19. ncbi request reprint Somatostatin receptors in malignant lymphomas: targets for radiotherapy?
    Virgil A S H Dalm
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 45:8-16. 2004
    ..Therefore, we investigated in vitro the characteristics of lymphoma tissues and lymphoid cell lines to evaluate whether lymphomas can be targets for radiotherapy...
  20. ncbi request reprint Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells
    Virgil A S H Dalm
    Dept of Internal Medicine, Rm Bd 240, Erasmus MC, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands
    Am J Physiol Endocrinol Metab 285:E344-53. 2003
    ....
  21. ncbi request reprint Octreotide exerts only acute, but no sustained, effects on MRI enhancement of liver metastases in carcinoid syndrome
    Menno T Zomerhuis
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Neuroendocrinology 82:41-8. 2005
    ..This study further shows that contrast-enhanced dynamic MRI can be a very useful tool for studying hemodynamic effects of medical therapies on liver metastases in patients with metastatic midgut carcinoids...
  22. ncbi request reprint Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth
    Peter M van Koetsveld
    Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 91:4537-43. 2006
    ..Despite efforts to develop new therapeutic regimens for metastatic ACC, surgery remains the mainstay of treatment. Interferons are known to exert tumor-suppressive effects in several types of human cancer...